News
Global Cannabis News & Analysis | Business of Cannabis
News · page 16
- Press releases
Why We Built PPX: From Advocacy to Growth
In 2017, when we launched Prohibition Partners, we set out with the goal to change the conversation around cannabis.
- Industry Trends
US Cannabis Rescheduling: A Victory or a Federal Trap?
US cannabis rescheduling, much like President Donald Trump who is rightly credited for finally pushing it forward, has sucked all the oxygen out of the room for the last two years.
- Investment & Finance
Business Brief: Safe Harbor Capitalises on Rescheduling Momentum with Financial Ecosystem Offering
Cannabis fintech Safe Harbor Financial is positioning itself to capitalise on the regulatory tailwinds created by federal rescheduling, launching new service partnerships and renegotiating core banking agreements in a bid to fill the severe financial infrastructure gap in the US cannabis industry.
- International Regulation
France’s Medical Cannabis Framework: Built for Patients or for Regulators?
The French medical cannabis market is now in the very final stage of decision-making before being implemented nationally, as the HAS presented its draft for the pricing and reimbursement strategy earlier this week.
- Industry Trends
New Report: Poland Medical Cannabis Market Data Shows Full Post-Ban recovery, With a Catch
Polish pharmacies dispensed nearly 5,450 kilograms of dried cannabis flower in 2025, a 12% increase from the prior year, according to new data obtained by Prohibition Partners.
- Medical Cannabis
Cannabis Europa Paris 2026: France’s Medical Cannabis Reimbursement Plans Revealed
Today (February 19, 2026), Cannabis Europa returns to the French capital for the first time since 2019 at a critical juncture for the incoming French medical cannabis industry.
- M&A Activity
Business Brief: Argent Biopharma’s Revenues Drop, Outgoings Rise Ahead of AusCann Deal
Argent Biopharma, formerly MGC Pharmaceuticals, has entered 2026 in a precarious financial position, according to its recently published quarterly figures.
- Industry Trends
CRS Report Suggests 280E Could be Unconstitutional for Cannabis Businesses
According to recent analysis from the Congressional Research Service, cannabis businesses may not need to wait for rescheduling to challenge the now-notorious 280E tax burden, suggesting that it may be unconstitutional.
- Industry Trends
AI: The Last Refuge of the Failed Cannabis Company
Late last month, NASDAQ-listed cannabis operator Flora Growth, which once operated one of Colombia’s largest outdoor cultivation facilities, became the latest to exit the cannabis industry, rebranding as an AI-focused digital asset firm ZeroStack Corp.
- Industry Trends
Access, Saturation, Consolidation: Why Denmark Foreshadows the Future of Europe’s Medical Cannabis Markets
As Europe’s medical cannabis markets continue to mature, an increasingly familiar pattern is beginning to emerge.
- Investment & Finance
Rescheduling Optimism Fades, Cannabis Stocks Follow
It is now nearly two months since President Donald Trump surprised the global cannabis industry by signing an executive order to drag the highly-anticipated cannabis rescheduling process out of the bureaucratic swamp.
- Medical Cannabis
France’s Long-Awaited Medical Cannabis Reimbursement Framework to Be Revealed Next Week
French authorities will present a first draft of the long-awaited pricing and reimbursement decree for medical cannabis on February 18, marking a critical milestone in the country’s drawn-out transition from pilot programme to permanent framework.
